The global pharmaceutical drying equipment market was valued at US$5.45 billion in 2023 and US$5.80 billion in 2024. It is projected to grow at a CAGR of 7.1% from 2024 to 2029, reaching a forecasted valuation of US$8.18 billion by the end of the period. This growth is primarily fueled by the expansion of manufacturing facilities, rising demand for biopharmaceuticals, and the rapid development of contract manufacturing organizations.

Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=24018886

What are the key drivers influencing the growth of the Market?

The primary driver for the market is the continuous expansion of pharmaceutical manufacturing facilities worldwide to meet the rising demand for medications treating chronic diseases. Increased global prevalence of conditions such as cancer and diabetes has prompted major investments, including Takeda Pharmaceuticals’ US$0.75 billion production facility in Japan and BeiGene’s biologics facility in the US. These expansions require innovative drying equipment to process active pharmaceutical ingredients effectively while maintaining high product quality.

Additionally, the surging demand for biopharmaceuticals, such as vaccines, antibodies, and hormones, significantly contributes to market growth. These heat-sensitive products often require specialized drying processes like lyophilization to ensure stability and efficacy during long-term storage and transport. The rapid development of Contract Manufacturing Organizations (CMOs) and CDMOs further bolsters demand as pharmaceutical companies increasingly outsource production to optimize costs and focus on core research activities.

What are the major restraints limiting the growth of the Market?

A significant restraint is the increasing demand for refurbished drying equipment, which offers a cost-effective alternative to expensive new machinery. This trend is particularly prevalent among startups and companies in emerging economies looking to reconcile operational requirements with limited budgets. The adoption of reconditioned units can slow the market for new equipment and potentially impact product quality if the refurbished machines lack updated operational formats or technological advancements.

Furthermore, the high capital cost and continuous maintenance requirements of advanced drying systems pose a financial burden. Small and medium-sized firms may find it challenging to bear the expenses associated with regular calibration and routine maintenance. Failure to maintain equipment properly can lead to ineffective drying, increased operational costs, and non-compliance with strict pharmaceutical industry regulations, which may discourage long-term investment in new machinery.

What emerging opportunities are expected to shape the future of the Market?

The loss of market exclusivity for several blockbuster drugs presents a major growth opportunity. Patents for high-profile drugs like GSK’s Dolutegravir and Merck & Co.’s Keytruda are scheduled to expire between 2025 and 2029, opening the door for generic and biosimilar producers to enter the market. To capture market share, companies like Sandoz are investing heavily in new biologics facilities, which will drive significant demand for cutting-edge drying technologies to ensure production quality.

The high growth potential of emerging markets also offers lucrative opportunities for stakeholders. As these regions experience a rising prevalence of chronic diseases and increased healthcare spending, the expansion of local pharmaceutical infrastructure is accelerating. Manufacturers can capitalize on this by providing specialized drying solutions tailored to the needs of rapidly growing pharmaceutical hubs in these developing economies.

What are the critical challenges faced by stakeholders in the Market?

One of the critical challenges is the higher maintenance and calibration requirements of pharmaceutical drying equipment. Inadequate maintenance can result in poor product quality and reduced equipment longevity, hampering the market’s overall performance. Manufacturers must balance the need for high-quality, compliant output with the substantial resources required to keep sophisticated machinery operating at peak efficiency.

Strict regulatory standards also pose a challenge, as companies must ensure that their drying processes do not compromise the efficacy or safety of active medicinal components. Navigating the complexities of global compliance while managing rising operation costs and competitive pressures from generic manufacturers requires constant innovation and strategic resource management from equipment providers and pharmaceutical producers alike.

Who are the leading players operating in the Market?

The global pharmaceutical drying equipment market is led by prominent players such as GEA Group (Germany), ATS Corporation (US), and Hosokawa Micron Group (Japan). Other key participants include Freund Corporation (Japan), I.M.A. Industria Macchine Automatiche S.p.A. (Italy), Syntegon Technology GmbH (Germany), and BUCHI Labortechnik AG (Switzerland). These companies focus on technological advancements and strategic acquisitions to maintain their competitive edge.

The market also features specialized players such as OPTIMA (Germany), MechaTech Systems Ltd. (Netherlands), BEW Engineering (India), Zirbus Technology GmbH (Germany), SPX Flow Inc. (US), and Yamato Scientific Co., Ltd. (Japan). Recent strategic developments, such as Syntegon’s acquisition of Azbil Telstar and GEA’s investment in a new pharmaceutical technology center, highlight the industry’s focus on expanding processing capabilities and innovation.

What are the key segments of the Market based on type, application, and end user?

Based on type, the freeze dryers segment is expected to possess the highest CAGR during the forecast period due to the rising demand for heat-sensitive biopharmaceuticals. Freeze-drying is essential for preserving the stability of over half of the biopharmaceutical products listed by the USFDA and EMA. Other segments by type include spray dryers, fluid bed dryers, and vacuum dryers, which are utilized based on specific formulation requirements.

In terms of end users, the market is classified into pharmaceutical and biotech companies, CDMOs, and research academies. In 2023, pharmaceutical and biotech companies held the largest market share, driven by their extensive manufacturing facility expansions. However, CDMOs are registered as the fastest-growing segment as the industry trends toward outsourcing manufacturing processes to reduce internal costs and increase operational flexibility.

Which regions are dominating and emerging in the Market?

The Asia Pacific region currently dominates the market, accounting for a 34.6% share in 2023. It is also projected to be the fastest-growing regional segment, reaching a valuation of USD 3.05 billion by 2029 at a CAGR of 8.4%. This dominance is fueled by the rapid expansion of manufacturing facilities in China, which serves as a global hub for API manufacturing, and India, which offers significant cost advantages and a skilled labor pool.

In addition to Asia Pacific, North America and Europe remain significant markets supported by advanced healthcare infrastructure and heavy investments in R&D. However, the highest growth rates are concentrated in the Asia Pacific due to rising prevalence of chronic diseases, increasing demand for affordable medications, and supportive government initiatives that encourage domestic and international pharmaceutical investment.

Inquire Before Buying-https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=24018886